New systemic therapy options for advanced sarcomas.

Item

http://www.wikidata.org/entity/Q36166394

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

New systemic therapy options for advanced sarcomas.

@ast

New systemic therapy options for advanced sarcomas.

@en

type

Item

label

New systemic therapy options for advanced sarcomas.

@ast

New systemic therapy options for advanced sarcomas.

@en

prefLabel

New systemic therapy options for advanced sarcomas.

@ast

New systemic therapy options for advanced sarcomas.

@en

P1476

New systemic therapy options for advanced sarcomas.

@en

P2093

Hans Gelderblom

http://www.w3.org/2001/XMLSchema#string

Winette T A van der Graaf

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Phase II study of imatinib in advanced chordoma.

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

P2888

s11864-012-0196-2

P304

306-317

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S11864-012-0196-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225095310

http://www.w3.org/2001/XMLSchema#string

P698

22661203

http://www.w3.org/2001/XMLSchema#string

P921

sarcoma

epithelioid sarcoma

P932

3419831

http://www.w3.org/2001/XMLSchema#string